Business Context and Reporting Period
This Form 8-K Current Report was filed by Eli Lilly and Company on July 5, 2024, regarding events occurring on June 5, 2024, and effective July 15, 2024. The filing addresses executive leadership changes within the company's finance organization.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It is a disclosure of personnel changes only.
Material Changes
- Departure of CFO: Anat Ashkenazi resigned as Executive Vice President and Chief Financial Officer to pursue opportunities outside the pharmaceutical industry.
- Interim Appointment: Gordon Brooks, currently Group Vice President, Controller, and Corporate Strategy, was appointed as Interim Chief Financial Officer effective July 15, 2024.
- Transition Plan: Ms. Ashkenazi will remain with the company through the end of July 2024 to facilitate the transition of responsibilities.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. No specific risks or contingencies related to financial operations were disclosed in this document. The appointment of Mr. Brooks is noted as an internal transition with no special arrangements or understandings influencing his selection.
Investor Verification Checklist
- Confirm the effective date of Gordon Brooks' interim CFO role (July 15, 2024).
- Verify the duration of Anat Ashkenazi's transition period (through end of July 2024).
- Review subsequent filings for the appointment of a permanent Chief Financial Officer.
- Check for any impact on the company's financial reporting calendar or investor relations strategy due to the leadership change.